Coronaviruses (CoVs) have emerged from animal reservoirs to cause severe and lethal disease in 23 humans, but there are currently no FDA approved antivirals to treat these infections. One class of 24 antiviral compounds, nucleoside analogues, mimics naturally occurring nucleosides to inhibit 25 viral replication. While these compounds have been successful therapeutics for several viral 26 infections, mutagenic nucleoside analogues, such as ribavirin and 5-fluorouracil, have been 27 ineffective at inhibiting CoVs. This has been attributed to the proofreading activity of the viral 28 3'-5' exoribonuclease (ExoN). β-D-N 4 -hydroxycytidine (NHC, EIDD-1931; Emory Institute for 29 Drug Development) has recently been reported to inhibit multiple viruses. Here, we demonstrate 30 that NHC inhibits both murine hepatitis virus (MHV) (EC 50 =0.17 M) and Middle East 31 respiratory syndrome CoV (MERS-CoV) (EC 50 = 0.56 M) with minimal cytotoxicity. NHC 32 inhibited MHV lacking ExoN-proofreading activity similarly to WT MHV, suggesting an ability 33 to evade or overcome ExoN activity. NHC inhibited MHV only when added early during 34 infection, decreased viral specific infectivity, and increased the number and proportion of G:A 35 and C:U transition mutations present after a single infection. Low-level NHC resistance was 36 difficult to achieve and was associated with multiple transition mutations across the genome in 37 both MHV and MERS-CoV. These results point toward a virus-mutagenic mechanism of NHC 38 inhibition in CoVs and indicate a high genetic barrier to NHC resistance. Together, these data 39 support further development of NHC for treatment of CoVs and suggest a novel mechanism of 40 NHC interaction with the CoV replication complex that may shed light on critical aspects of 41 replication. 42 on October 13, 2019 at UNIV OF OTAGO http://jvi.asm.org/ Downloaded from IMPORTANCE 43 The emergence of coronaviruses (CoVs) into human populations from animal reservoirs has 44 demonstrated their epidemic capability, pandemic potential, and ability to cause severe disease. 45 However, no antivirals have been approved to treat these infections. Here, we demonstrate the 46 potent antiviral activity of a broad-spectrum ribonucleoside analogue, β-D-N 4 -hydroxycytidine 47 (NHC), against two divergent CoVs. Viral proofreading activity does not markedly impact 48 sensitivity to NHC inhibition, suggesting a novel interaction between a nucleoside analogue 49 inhibitor and the CoV replicase. Further, passage in the presence of NHC generates only low-50 level resistance, likely due to the accumulation of multiple, potentially deleterious, transition 51 mutations. Together, these data support a mutagenic mechanism of inhibition by NHC and 52 further support the development of NHC for treatment of CoV infections. 53 on October 13, 2019 at UNIV OF OTAGO http://jvi.asm.org/ Downloaded from RESULTS 98 NHC inhibits MHV and MERS-CoV replication with minimal cytotoxicity. 99 NHC (Fig. 1) has potent broad-spectrum antiviral activity against many RNA viral families (31-100 36). We first determined if NHC also inhibits CoV replication using a dose-response experiment 101 with two divergent -CoVs: the model CoV, MHV, and the epidemically circulating zoonotic 102
INTRODUCTION 54
The emergence of severe acute respiratory syndrome (SARS) in 2002 and Middle East 55 respiratory syndrome (MERS) in 2012 has underscored the ability of coronaviruses (CoVs) to 56 cause lethal disease in humans (1, 2) . MERS-CoV continues to infect humans in the Middle East 57 and four additional human CoVs (HCoVs), HCoV-229E, HCoV-NL63, HCoV-OC43, and 58
HCoV-HKU1, continue to circulate globally and cause respiratory disease (3) (4) (5) (6) . The continued 59 circulation of SARS-and MERS-like CoVs that can replicate efficiently in primary human 60 airway cells in bat populations further demonstrates the potential for CoVs to emerge and cause 61 severe disease in the future (7-10). While SARS-CoV and MERS-CoV outbreaks have been 62 controlled largely through public health measures (11) (12) (13) , the potential for future outbreaks 63 highlights the need for safe and effective therapeutics to combat CoV infections. There are 64 currently no approved therapeutics or vaccines for any human CoV infection. Previous efforts to 65 treat CoV infections with existing antivirals did not conclusively benefit clinical outcome; thus, 66 the current standard of care remains mostly supportive (14) (15) (16) . 67
Several targets for direct-acting antivirals are being investigated to treat CoV infections 68 (17) (18) (19) . Because the viral replication machinery performs an essential role in genome 69 replication, therapeutics approved to treat multiple different viral infections are aimed at this 70 target (20) . Many approved antivirals are classified as nucleoside analogues, compounds that 71 mimic natural nucleosides to inhibit viral replication (21) . Inhibition by nucleoside analogues 72 can be accomplished through a variety of mechanisms. Common mechanisms of action include 73 incorporation of the analogue by the viral polymerase to induce premature termination of strand 74 on October 13, 2019 at UNIV OF OTAGO http://jvi.asm.org/ Downloaded from synthesis or loss of essential genetic information through mutagenesis (22) (23) (24) (25) . A previous study 75 reported that the nucleoside analogues ribavirin (RBV) and 5-fluorouracil (5-FU) did not 76 potently inhibit CoVs, and this finding was attributed to the proofreading capabilities of the viral 77 3'-5' exoribonuclease (ExoN) (26) . Recent reports have demonstrated the inhibition of WT 78
CoVs by nucleoside analogues such as galidesivir (BCX4430) and remdesivir (GS-5734) (27-79 29) . While these compounds have shown efficacy against CoVs, administration of multiple 80 compounds simultaneously may be required to effectively treat CoV infections and control the 81 emergence of drug resistance, as has been demonstrated for other viral infections (30) . 82 -D-N 4 -hydroxycytidine (NHC) (EIDD-1931, Emory Institute for Drug Development), a 83 cytidine analogue, has recently been shown to inhibit multiple viruses, including chikungunya 84 virus, Venezuelan equine encephalitis virus, respiratory syncytial virus, hepatitis C virus, 85 norovirus, influenza A and B viruses, . Previous reports have 86 demonstrated an increased introduction of transition mutations in viral genomes after treatment 87 as well as a high genetic barrier to resistance (31, 36) . Antiviral activity of NHC has also been 88 reported against the human -CoV HCoV-NL63, as well as the -CoV SARS-CoV (38) (39) (40) . 89
Neither NHC mechanism of action nor NHC resistance have been described for any CoVs to 90 date. 91
In this study, we investigated NHC inhibition and resistance in two divergent -CoVs, 92 murine hepatitis virus (MHV) and MERS-CoV. We show that NHC potently inhibits WT MHV 93 and MERS-CoV with minimal cytotoxicity. We also demonstrate that MHV ExoN proofreading 94 activity has a limited but measurable effect on sensitivity to NHC. We observe an NHC 95 inhibition profile consistent with a mutagenic mechanism of action featuring an accumulation of 96 transition mutations, indicative of a high genetic barrier to resistance. 97 on October 13, 2019 at UNIV OF OTAGO http://jvi.asm.org/ Downloaded from 7 approximately 10-fold at the highest tested concentration of NHC in both MHV-infected cell 120 monolayers ( Fig. 3B ) and supernatants (Fig. 3C ). In contrast, viral titer was reduced up to 5,000-121 fold at this concentration. We therefore calculated the ratio of infectious virus per viral RNA 122 genome copy number normalized to the untreated control (specific infectivity) after NHC 123 treatment and found that the specific infectivity of WT MHV was reduced in a dose-dependent 124 manner after treatment with increasing concentrations of NHC ( Fig. 3D ). Together, these data 125 are consistent with a mutagenic mechanism of NHC anti-CoV activity. 126
127

NHC treatment increases transition mutations present across the MHV genome. 128
To directly test the effect of NHC treatment on mutational burden, we treated WT MHV with 129 increasing concentrations of NHC and performed full-genome next-generation sequencing 130 (NGS) on viral populations released after a single round of infection. Our data demonstrate a 131 dose-dependent increase in mutations present at low frequencies (<5 % of viral population) 132 across the genome after treatment with increasing concentrations of NHC ( Fig. 4A-C) . Further 133 analysis of the types of mutations introduced by NHC revealed an increase in the total number of 134 transition mutations with increasing NHC concentrations ( Fig. 4D -F). The relative proportion of 135 G:A and C:U transitions among all observed mutations was increased by 13-15% in the presence 136 of 2 M NHC and 36-40% in the presence of 4 M NHC compared to the vehicle control ( Fig.  137 4G, H). Conversely, the relative proportion of A:G and U:C transitions was decreased with 138 increasing NHC concentrations compared to the vehicle control ( Fig. 4G, H) . Together, these 139 results demonstrate that NHC treatment during a single round of WT MHV infection causes 140 predominantly G:A and C:U transition mutations that are detectable at low frequencies across the 141 genome. These data further support a mutagenic mechanism of action for NHC inhibition of WT 142 Mutagenic nucleoside analogues, such as RBV and 5-fluorouracil (5-FU), have been ineffective 146 at potently inhibiting WT CoVs due to the ExoN proofreading activity (26). A proofreading-147 deficient MHV mutant, ExoN(-), displays increased sensitivity to previously tested nucleoside 148 analogues, indicating that proofreading dampens inhibition by these compounds (26, 38, 39) . 149
Thus, we tested the sensitivity of ExoN(-) MHV to NHC inhibition. Our results indicate that 150 NHC decreases viral titer of both WT and ExoN(-) MHV in a dose-dependent manner, but that 151 ExoN(-) MHV demonstrates a statistically significant increase in sensitivity to NHC inhibition 152 compared to WT MHV (Fig. 5A ). However, this difference is reflected in only a modest decrease 153 To better understand the development and impact of NHC resistance in CoVs, we passaged two 160 lineages of WT MHV in thirty times in the presence of increasing concentrations of NHC and 161 tested the sensitivity of passage 30 (p30) MHV populations to NHC inhibition. We found that the 162 lineage 1 (MHV p30.1) viral population showed no change in sensitivity to NHC compared to 163 WT MHV ( Fig. 6A ). However, lineage 2 (MHV p30.2) showed a decrease in sensitivity to NHC 164 inhibition in a titer-reduction assay, especially at higher concentrations of compound. Fig. 6B ). This suggests that MHV passage resulted in minimal resistance to NHC. We next 168 sought to determine if passaging WT MHV in the presence of NHC altered the replication 169 capacity of these viruses. We found that both lineages showed a delay in replication but 170 ultimately reached similar peak titers as WT MHV (Fig. 6C ). This delay in replication suggests 171 that MHV p30 viruses are less fit than WT MHV. 172
To identify mutations associated with these phenotypes after passage, we sequenced 173 complete genomes of MHV p30.1 and MHV p30.2. Both lineages passaged in the presence NHC 174 had accumulated over 100 consensus mutations distributed across the genome ( Fig. 6D , E; Table  175 S1). By comparison, a previous study reported that WT MHV accumulated only 23 total 176 mutations after 250 passages in the absence of drug (39). Further analysis of the p30 MHV 177 mutational profile demonstrated that slightly more of the total mutations in both lineages were 178 synonymous changes that did not result in an amino acid change as opposed to nonsynonymous 179 changes that did alter amino acid sequence ( Fig. 6F ; Table S1 ). Additionally, the vast majority of 180 mutations in both lineages were transition mutations resulting in a purine-to-purine or 181 pyrimidine-to-pyrimidine change ( Fig. 6G ). Both lineages contained only two transversion 182 mutations resulting in a purine-to-pyrimidine or pyrimidine-to-purine change. Though all 183 possible transition mutation types were detected in both viral lineage populations, the majority in 184 both passage lineages were G:A transitions ( Fig. 6H ), which is consistent with the MHV NGS 185 data ( Fig. 4) . To determine if the mutational profile at p30 was consistent with an earlier passage, 186
we analyzed the whole genome of both lineage 1 and 2 at passage 19 (p19). Both lineages 187 demonstrated fewer mutations at p19 than at p30, but the profiles of synonymous vs. 188 on October 13, 2019 at UNIV OF OTAGO http://jvi.asm.org/ Downloaded from nonsynonymous changes and the transition mutations were similar ( Fig. S1 ; Table S2 ). 189
To determine whether the lack of robust resistance to NHC was broadly applicable across 190 -CoVs, we assessed the capacity of MERS-CoV to evolve resistance to NHC. Like MHV, we 191 passaged two lineages of MERS-CoV 30 times in the presence of increasing concentrations of 192 NHC and tested the sensitivity of these lineages to inhibition by NHC. Compared to CoV passaged in the absence of drug, both MERS-CoV NHC p30.1 and p30. Table S3 ) and 41 201 consensus mutations in MERS-CoV NHC p30.2 ( Fig. 7E ; Table S3 ) that were randomly 202 distributed across the genome. Both MERS-CoV NHC p30.1 and MERS-CoV NHC p30.2 203 accumulated nonsynonymous and synonymous mutations in roughly equal proportions ( Fig. 7F ). 204
Like in MHV, the mutations detected in MERS-CoV p30 lineages were predominantly transition 205 mutations ( Fig. 7G ). Further analysis of these mutations revealed that the predominant type of 206 transition was lineage-dependent. The majority of transition mutations in MERS-CoV NHC 207 p30.1 were G:A transitions, as was observed in both p30 MHV lineages, whereas MERS-CoV 208 NHC p30.2 contained a similar number of each type (Fig. 7H ). These results indicate that 209
MERS-CoV can achieve low-level resistance to NHC and that development of resistance is 210
associated with the accumulation of multiple transition mutations. Together, our data suggest 211 on October 13, 2019 at UNIV OF OTAGO http://jvi.asm.org/ Downloaded from NHC acts as a mutagen and that it poses a high genetic barrier to resistance for β-CoVs. 212
DISCUSSION 213
In this study, we demonstrate that NHC potently inhibits the divergent -CoVs MHV and 214 MERS-CoV. Our data are consistent with a virus mutagenic mechanism of action as evidenced 215 by a decrease in specific infectivity and an increase in G:A and C:U transition mutations present 216 at low frequencies across the genome after treatment with NHC. We also demonstrate that robust 217 resistance to NHC is difficult to achieve in both MHV and MERS-CoV. Both WT MHV and 218 ExoN(-) MHV are sensitive to NHC inhibition, suggesting that NHC is able to overcome ExoN-219 mediated proofreading to inhibit WT CoVs and that it interacts with CoVs differently than other 220 previously tested nucleoside analogues. 221 222
Utility of the broad spectrum antiviral NHC as a pan-CoV therapeutic. 223
Early work with NHC focused on the mutagenic effects of this compound in multiple bacterial 224 systems (40) (41) (42) activity, or ExoN(-) viruses, are more sensitive to inhibition by nucleoside analogues, especially 244 RBV and 5-FU (26, 38, 39, 45) . This increased sensitivity has been attributed to an inability of 245 ExoN(-) to efficiently remove incorrect nucleosides (46). However, we observed a minimal 246 change in NHC sensitivity between WT MHV and ExoN(-) MHV, especially by EC 90 . This 247 suggests that NHC interacts with the CoV replicase differently than other previously tested 248 nucleoside analogues. One explanation is that NHC may evade removal by the proofreading 249
ExoN. Studies investigating nucleosides that inhibit DNA viruses have suggested an inability of 250 the viral exonuclease to efficiently excise some nucleoside analogues (47, 48 (46). This suggests that the CoV polymerase could be naturally 257 more prone to make these types of errors, which are then magnified by NHC. This could lead to 258 a scenario where ExoN cannot prevent dipping below the error threshold, ultimately resulting in 259 lethal mutagenesis and similar inhibition of both WT MHV and ExoN(-) MHV (51). 260
Several nucleosides including the mutagenic RBV have multiple demonstrated 261 mechanisms other than direct incorporation into the genome (52, 53). Thus, another explanation 262 for the unique potency of NHC in the presence of an active proofreading ExoN is that it may 263 inhibit viral replication by additional mechanisms beyond mutagenesis. Indeed, previous reports 264 have suggested that NHC may also interfere with the RNA secondary structure or virion release 265 to cause inhibition (31, 36). Further, exogenous C or U in the presence of NHC could rescue 266 viral replication in in HCV, Chikungunya virus, RSV, and Influenza A virus (32, 34, 36) , 267
indicating that NHC competes with exogenous nucleosides at some stage prior to viral inhibition. 268
These results raise the possibility that NHC could inhibit a process that results in similar 269 inhibition of these viruses by a mechanism unrelated to ExoN. Thus, future studies will be 270 CoV, the p30 lineage that demonstrated a greater change in sensitivity to NHC was the lineage 295 that had fewer overall mutations (Fig. 6, 7) . Both MHV passage lineages replicated less well than 296 WT MHV, suggesting that the accumulation of mutations during passage may negatively impact 297 viral fitness and the ability of MHV to evolve robust resistance to NHC. Further, the MHV 298 lineage that did not result in changed sensitivity to NHC by p30 (MHV p30.1) had fewer 299 mutations present at consensus by p19 than the other lineage ( Fig. S1 ). Thus, it is possible that 300 the accumulation of deleterious mutations counteracts potential benefits of resistance mutations 301 (63). If this is the case, mutations promoting NHC resistance would need to arise early during 302 on October 13, 2019 at UNIV OF OTAGO http://jvi.asm.org/ Downloaded from passage to help mitigate the accumulation of excess deleterious mutations. Alternatively, the 303 inability to evade inhibition by NHC may lead to the accumulation of a greater number of NHC-304 associated transitions and ultimately a higher mutational burden that may impact viral fitness 305 (64, 65). Together, our results support the hypothesis that establishment of resistance to NHC in 306
CoVs requires a delicate balance of resistance-promoting mutations, viral fitness, and 307 accumulation of deleterious mutations. Thus, defining the roles of individual NHC resistance-308 associated mutations will be an important goal for future studies. Overall, our results support Viruses. All work with MHV was performed using the recombinant WT strain MHV-A59 317 (GenBank accession number AY910861 (67)). MERS-CoV stocks were generated from cDNA 318 clones (GenBank accession number JX869059 (68)). the TRIzol reagent (Invitrogen) after 20 hours, followed by extraction and quantification as 359 described above. Viral titer was determined by plaque assay. The specific infectivity was 360 calculated as PFU divided by supernatant genome RNA copy number. This ratio was then 361 normalized to the vehicle control. 362 NGS studies. Subconfluent DBT cells were infected with WT MHV at an MOI of 0.01 PFU/cell 363 and treated with the indicated concentrations of NHC. Supernatant was collected 24 hours post-364 infection. Purified viral RNA was submitted to GENEWIZ for library preparation and 365 sequencing. Briefly, after quality controls, viral RNAs were randomly fragmented using heat. 366
Libraries were prepared and sequenced on the Illumina HiSeq platform. 367 GENEWIZ performed base-calling and read demultiplexing. Trimmomatic was used to trim 368 adapter contaminants and reads shorter than 36 basepairs and filter low quality bases (Q-score 369 <30) (71). The paired-end fastq reads were then aligned to the MHV genome using Bowtie2 to 370 generate a SAM file (72). SAMtools was used to process the resultant alignment file and 371 calculate coverage depth at each nucleotide, generating a sorted and indexed BAM file. LoFreq 372 was used to call substitution variants, including low-frequency variants, and generate a variant 373 file (73). The Bash shell and Excel were used to further process and analyze the resultant vcf file. 374
A frequency of 0.001 was used as a cutoff for variants, consistent with previous reports (74). 375
Absolute numbers of mutations are reported for each NHC treatment. The percentage of the total 376 mutations for each specific mutation type was calculated using these numbers. The difference in 377 percentage for each class of mutation after treatment as compared with vehicle control is referred 378 to as the relative proportion of these mutations. 379 MHV population passage in the presence of NHC. WT MHV was passaged in triplicate in 380 increasing concentrations of NHC, from 1 μM to a maximum of 5 μM. Infection was initiated 381 for passage 1 at MOI = 0.1 PFU/cell. Viral supernatants were harvested from each viral lineage 382 and frozen when the cell monolayer demonstrated 80% cytopathic effect (CPE) or after 24 hrs. A 383 constant volume of 16 μL was used to initiate subsequent passages. All three lineages were 384 maintained until passage 16 when lineage 3 demonstrated no visible CPE upon multiple attempts 385 at varying concentrations. Lineage 1 and 2 were maintained until passage 30. After each passage, 386 total RNA was harvested from infected cell monolayers using the TRIzol reagent. Viral RNA 387 was extracted from passage 19 and passage 30 samples and reverse transcribed using SuperScript 388 III, followed by generation of 12 PCR amplicons to cover the whole genome. Dideoxy amplicon 389 sequencing was performed by GENEWIZ and analyzed to identify mutations present at greater 390 than 50% of total using MacVector. Viral mutation maps depicting the identified mutations were 391 generated using MacVector. 
